The purpose of this study is to help researchers see if the combination of amivantamab and lazertinib is safe and effective in patients with NSCLC who have a specific mutation in the EGFR (epidermal growth factor receptor) gene.
Learn more about the COPERNICUS trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
